Abstract
Between October 2015 and August 2016, Zimbabwe conducted the Zimbabwe Population-Based HIV Impact Assessment (ZIMPHIA) cross-sectional survey to determine progress toward epidemic control. Of 25,131 eligible adults aged 15–64 years, 20,577 (81.8%) consented to face-to-face questionnaire and biomarker testing in this nationally representative household survey. Home-based rapid HIV testing was performed using Determine, First Response, and STAT-PAK as the tiebreaker. HIV-positive tests were confirmed in a laboratory using Geenius HIV-1/2; viral load (VL) was measured using Roche TaqMan and BioMerieux NucliSENS. Recency of infection was tested using Sedia HIV-1 Limiting Antigen (LAg)-Avidity. Presence of antiretroviral (ARV) drugs was detected using high performance liquid chromatography/mass spectrometry (HPLC/MS). The recent infection testing algorithm included LAg-avidity enzyme immunoassay [normalized optical density (ODn ≤1.5), VL ≥1,000 copies/mL, and absence of ARV drugs]. Weighted annual HIV incidence was compared with United Nations Joint Programme on HIV/AIDS (UNAIDS) Spectrum models estimates. Overall, 26 of 2,901 HIV-seropositive individuals had a recent infection (men, 8; women, 18). Overall weighted annual incidence among persons aged 15–64 years was 0.42% [95% confidence interval (CI): 0.25–0.59] and was 0.44% (95% CI: 0.25–0.62) for those aged 15–49 years, similar to 2016 Spectrum model estimate (0.54%, 95% CI: 0.49–0.66) for this age group. Among persons aged 15–49 years, HIV prevalence was 13.35% (95% CI: 12.71–14.02), estimated HIV-positive individuals were 968,951 (95% CI: 911,473–1,026,430), of these, 41,911 (95% CI: 37,412–44,787) were annual-new infections, and this was similar to 2016 Spectrum estimates. The observed HIV incidence in ZIMPHIA 2015–2016 validated the 2016 Spectrum estimates and Zimbabwe's progress toward epidemic control.
Get full access to this article
View all access options for this article.